ראשי » About Multiple Sclerosis » Therapeutic information by pharmaceutical companies

Therapeutic information by pharmaceutical companies

11 March 2021

The Committee for the Expansion of the Medical Health Basket Services has confirmed that starting from 2021, BMS’s (Bristol Myers Squibb) drug will be included

Zeposia (Ozanimod) – a new drug in the national health basket for multiple sclerosis patients
30 December 2018

Q. What is fingolimod/Gilenya? A. Gilenya is a once daily oral treatment for relapsing MS. It works by binding to a docking site (sphingosine-1-phosphate receptor,

FAQ About FDA Approval of Oral Gilenya for Children and Adolescents 10 and Older with Relapsing MS
02 March 2016

Background: Maintaining cognitive function in multiple sclerosis is a major concern. It is a priority to identify factors that can help preserve cognition, in addition

Relation between cognitive function and physical activity in multiple sclerosis patients treated with interferon beta-1b – the CogniPlus study
02 March 2016

Background: Patients with clinically isolated syndrome (CIS) who had early treatment with interferon beta-1b in the BENEFIT trial had significantly better clinical outcomes up to

MRI results in patients with CIS treated with interferon beta-1b: 11-year follow up in BENEFIT (BENEFIT 11)
19 October 2015

The results from a phase III clinical trial of Ocrelizumab in primary progressive MS are announced at ECTRIMS There are currently no approved disease-modifying therapies

Positive results for people with primary progressive MS
01 October 2015

Objective: Determine molecular effect of Vitamin D3 on interferon-beta response in mononuclear cells. Background: Oral vitamin D has additive effects on IFN-b therapy in reducing

Vitamin D enhances interferon-beta-1b response in multiple sclerosis
08 August 2015

Introduction: The BENEFIT trial demonstrated improved clinical outcomes in patients with a clinically-isolated syndrome (CIS) and early treatment with interferon beta-1b up to 11 years

Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11)
08 August 2014

Data from single-arm extension of head-to-head TRANSFORMS study show sustained reduction in relapses and rate of brain volume loss in patients on continuous Gilenya treatment

Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
01 May 2012

Results of a large randomized trial have shown that the combination interferon beta-1a and Gatiramer Acetate was not more effective than either agent alone on

CombiRx: Interferon and Glatiramer Combo in MS Susan Jeffrey
01 April 2012

Abstract: Enhancing quality of life (QoL) is an important objective of disease-modifying therapies in multiple sclerosis (MS). Strategies to substantiate the effect on QoL and

Quality of life and Depression in Multiple Sclerosis Patients: Longitudinal Results of the BetaPlus Study
Previous Next
Close
Test Caption
Test Description goes like this